PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer

Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61

ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy

Li, C., Li, W., Xiao, J., Jiao, S., Teng, F., Xue, S., Zhang, C., Sheng, C., Leng, Q., Rudd, C. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404578 · Cited by 60

The Multifaceted Role of Regulatory T Cells in Breast Cancer

Kos, K., & de Visser, K. E. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042920-104912 · Cited by 58

Immune checkpoint inhibitors in older adults

Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0534-9 · Cited by 59

Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer

Chen, Z., Yuan, Y.-C., Wang, Y., Liu, Z., Chan, H. J., & Chen, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3446-8 · Cited by 59

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

Bassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1497 · Cited by 58

Immunogenic sonodynamic therapy for inducing immunogenic cell death and activating antitumor immunity

Wang, T., Peng, W., Du, M., & Chen, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167105 · Cited by 58

Immunogenicity of pembrolizumab in patients with advanced tumors

van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0663-4 · Cited by 57

IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer

Wang, L., Miyahira, A. K., Simons, D. L., Lu, X., Chang, A. Y., Wang, C., Suni, M. A., Maino, V. C., Dirbas, F. M., Yim, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1373 · Cited by 55

Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor

Adhikary, S., Chakravarti, D., Terranova, C., Sengupta, I., Maitituoheti, M., Dasgupta, A., Srivastava, D. K., Ma, J., Raman, A. T., Tarco, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08986-5 · Cited by 57

Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy

Ji, P., Sun, W., Zhang, S., Xing, Y., Wang, C., Wei, M., Li, Q., Ji, G., & Yang, G. (2023) · Advanced Science · doi:10.1002/advs.202301789 · Cited by 57

Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy

Sidhom, J.-W., Oliveira, G., Ross-MacDonald, P., Wind-Rotolo, M., Wu, C. J., Pardoll, D. M., & Baras, A. S. (2022) · Science Advances · doi:10.1126/sciadv.abq5089 · Cited by 57

Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma

Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57

Cell Fate Reprogramming in the Era of Cancer Immunotherapy

Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56

Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε

Sviderskiy, V. O., Blumenberg, L., Gorodetsky, E., Karakousi, T. R., Hirsh, N., Alvarez, S. W., Terzi, E. M., Kaparos, E., Whiten, G. C., Ssebyala, S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.016 · Cited by 56

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients

Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53

Therapeutic Cancer Vaccines—T Cell Responses and Epigenetic Modulation

Kartikasari, A. E. R., Prakash, M. D., Cox, M., Wilson, K., Boer, J. C., Cauchi, J. A., & Plebanski, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03109 · Cited by 54

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

Goss, G. D., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Guclu, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0775 · Cited by 55

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors

DeNardo, D. G., Galkin, A., Dupont, J., Zhou, L., & Bendell, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003005 · Cited by 53

Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies

Liu, X., Xu, D., Huang, C., Guo, Y., Wang, S., Zhu, C., Xu, J., Zhang, Z., Shen, Y., Zhao, W., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1929-9 · Cited by 53

Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer

Wu, J., Li, X., Teng, X., Rubin, D. L., Napel, S., Daniel, B. L., & Li, R. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1039-2 · Cited by 53

Human leukocyte immunoglobulin-like receptors in health and disease

Redondo-García, S., Barritt, C., Papagregoriou, C., Yeboah, M., Frendeus, B., Cragg, M. S., & Roghanian, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282874 · Cited by 53

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells

Chen, M., Sharma, A., Lin, Y., Wu, Y., He, Q., Gu, Y., Xu, Z. P., Monteiro, M., & Gu, W. (2019) · BMC Cancer · doi:10.1186/s12885-019-5364-3 · Cited by 53

Immunotherapies targeting stimulatory pathways and beyond

Marin-Acevedo, J. A., Kimbrough, E. O., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01085-3 · Cited by 52

Omics Technologies Improving Breast Cancer Research and Diagnostics

Orsini, A., Diquigiovanni, C., & Bonora, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612690 · Cited by 52

Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis

Singleton, D. C., Rouhi, P., Zois, C. E., Haider, S., Li, J.-L., Kessler, B. M., Cao, Y., & Harris, A. L. (2015) · Oncogene · doi:10.1038/onc.2014.396 · Cited by 52

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity

Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K. C., Siddiquee, A., You, D., Realubit, R., et al. (2021) · doi:10.1101/2021.10.03.462951 · Cited by 51

Developing biomarker-specific end points in lung cancer clinical trials

Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities

Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing

Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma

Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50

Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers

Thagaard, J., Stovgaard, E. S., Vognsen, L. G., Hauberg, S., Dahl, A., Ebstrup, T., Doré, J., Vincentz, R. E., Jepsen, R. K., Roslind, A., et al. (2021) · Cancers · doi:10.3390/cancers13123050 · Cited by 50

Concurrent loss of the Y chromosome in cancer and T cells impacts outcome

Chen, X., Shen, Y., Choi, S., Abdel-Hafiz, H. A., Basu, M., Hoelzen, L., Tufano, M., Kailasam Mani, S. K., Ranjpour, M., Zhu, J., et al. (2025) · Nature · doi:10.1038/s41586-025-09071-2 · Cited by 50

New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses

Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50

Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors

Sampedro-Núñez, M., Serrano-Somavilla, A., Adrados, M., Cameselle-Teijeiro, J. M., Blanco-Carrera, C., Cabezas-Agricola, J. M., Martínez-Hernández, R., Martín-Pérez, E., Muñoz de Nova, J. L., Díaz, J. Á., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36129-1 · Cited by 49

Laser direct-write onto live tissues: a novel model for studying cancer cell migration

Burks, H. E., Phamduy, T. B., Azimi, M. S., Saksena, J., Burow, M. E., Collins‐Burow, B. M., Chrisey, D. B., & Murfee, W. L. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25363 · Cited by 48

The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy

Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48

The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies

Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48

GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.

(2020) · PubMed Central · Cited by 47

Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

Iwata, H., Inoue, K., Kaneko, K., Ito, Y., Tsugawa, K., Hasegawa, A., Nakagawa, S., Kuratomi, H., & Tamura, K. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz135 · Cited by 46

PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation

Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0145 · Cited by 46

A Review of Imputation Strategies for Isobaric Labeling-Based Shotgun Proteomics

Bramer, L. M., Irvahn, J., Piehowski, P. D., Rodland, K. D., & Webb-Robertson, B.-J. M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00123 · Cited by 47

Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture

Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46

GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer

Kumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00438-6 · Cited by 45

Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer

Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44

Immunotherapies for pediatric cancer: current landscape and future perspectives

Hutzen, B., Paudel, S. N., Naeimi Kararoudi, M., Cassady, K. A., Lee, D. A., & Cripe, T. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09819-z · Cited by 44

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model

Padrón, Á., Hurez, V., Gupta, H. B., Clark, C. A., Pandeswara, S. L., Yuan, B., Svatek, R. S., Turk, M. J., Drerup, J. M., Li, R., et al. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.025 · Cited by 44

EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy

Zhou, X., Wang, M., Katsyv, I., Irie, H., & Zhang, B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty325 · Cited by 43

Efferocytosis Creates a Tumor Microenvironment Supportive of Tumor Survival and Metastasis

(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.666 · Cited by 44

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Shemesh, C. S., Chanu, P., Jamsen, K., Wada, R., Rossato, G., Donaldson, F., Garg, A., Winter, H., Ruppel, J., Wang, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0791-x · Cited by 43

Distal CpG islands can serve as alternative promoters to transcribe genes with silenced proximal promoters

Sarda, S., Das, A., Vinson, C., & Hannenhalli, S. (2017) · Genome Research · doi:10.1101/gr.212050.116 · Cited by 43

Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors

Tsimberidou, A.-M., Vo, H. H., Subbiah, V., Janku, F., Piha-Paul, S., Yilmaz, B., Gong, J., Naqvi, M. F., Tu, S.-M., Campbell, M., et al. (2021) · The Oncologist · doi:10.1002/onco.13682 · Cited by 43

Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy

Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39

Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model

Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42

Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy

Leone, R. D., Horton, M. R., & Powell, J. D. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.014 · Cited by 42

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40

BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.

Biswas, K., Philip, S., Yadav, A., Martin, B. K., Burkett, S., Singh, V., Babbar, A., North, S. L., Chang, S., & Sharan, S. K. (2018) · Nature Communications · doi:10.1038/s41467-018-03020-6 · Cited by 41

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000219 · Cited by 41

Immune checkpoint inhibitors for multiple myeloma immunotherapy

Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40

Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40

Recent advances in exosome-based immunotherapy applied to cancer

Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296857 · Cited by 40

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients

Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.006 · Cited by 40

Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice

Yassin, M., Sadowska, Z., Djurhuus, D., Nielsen, B., Tougaard, P., Olsen, J., & Pedersen, A. E. (2019) · Immunology · doi:10.1111/imm.13093 · Cited by 38

Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers

Wang, Y., Chen, D., Liu, Y., Shi, D., Duan, C., Li, J., Shi, X., Zhang, Y., Yu, Z., Sun, N., et al. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05992-w · Cited by 39

Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders

Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39

Colorectal Cancer Immunotherapy: State of the Art and Future Directions

Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39

The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures

Li, R., Berglund, A., Zemp, L., Dhillon, J., Putney, R., Kim, Y., Jain, R. K., Grass, G. D., Conejo-Garcia, J., & Mulé, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694079 · Cited by 39

Data-Driven Mathematical Model of Osteosarcoma

Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39

Exosomes in cancer immunoediting and immunotherapy

Zhao, Y., Liu, L., Sun, R., Cui, G., Guo, S., Han, S., Li, Z., Bai, T., & Teng, L. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.12.001 · Cited by 39

Challenges targeting cancer neoantigens in 2021: a systematic literature review

Chen, I., Chen, M. Y., Goedegebuure, S. P., & Gillanders, W. E. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1935248 · Cited by 39

T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases

McKinney, E. F., & Smith, K. G. (2016) · Immunology & Cell Biology · doi:10.1038/icb.2016.81 · Cited by 36

Photodynamic therapy of lung cancer, where are we?

Crous, A., & Abrahamse, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932098 · Cited by 38

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

Sweis, R. F., & Luke, J. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.012 · Cited by 37

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37

Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia

Goncalves, M. D., & Farooki, A. (2022) · Integrative Cancer Therapies · doi:10.1177/15347354211073163 · Cited by 37

Single-cell transcriptogenomics reveals transcriptional exclusion of ENU-mutated alleles

Li, W., Calder, R. B., Mar, J. C., & Vijg, J. (2015) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2015.01.002 · Cited by 34

Aging is associated with an expansion of CD49fhi mammary stem cells that show a decline in function and increased transformation potential

Dong, Q., Gao, H., Shi, Y., Zhang, F., Gu, X., Wu, A., Wang, D., Chen, Y., Bandyopadhyay, A., Yeh, I.-T., et al. (2016) · Aging · doi:10.18632/aging.101082 · Cited by 29

Epigenetic mechanisms of tumor resistance to immunotherapy

Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36

Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning

Gupta, S., Belouali, A., Shah, N. J., Atkins, M. B., & Madhavan, S. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00109 · Cited by 36

The center for causal discovery of biomedical knowledge from big data

Cooper, G. F., Bahar, I., Becich, M. J., Benos, P. V., Berg, J., Espino, J., Glymour, C., Jacobson, R. C., Kienholz, M., Lee, A. V., et al. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv059 · Cited by 36

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

Gallagher, E. J., Moore, H., Lacouture, M. E., Dent, S. F., Farooki, A., Goncalves, M. D., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00613-x · Cited by 36

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35

Immune classification of osteosarcoma

Le, T., Department of Mathematics and Statistics, U. O. M. A., Su, S., & Shahriyari, L. (2021) · Mathematical Biosciences and Engineering · doi:10.3934/mbe.2021098 · Cited by 35

The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: A comprehensive review and future perspectives

Silva, R., Gullo, I., & Carneiro, F. (2016) · Porto Biomedical Journal · doi:10.1016/j.pbj.2016.03.004 · Cited by 35

Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer

Principe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35

CRISPR screens identify gene targets at breast cancer risk loci

Tuano, N. K., Beesley, J., Manning, M., Shi, W., Perlaza-Jimenez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D., Civitarese, A., McCue, K., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02898-w · Cited by 30

Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto’s disease and diabetes mellitus: a case report

Yonezaki, K., Kobayashi, T., Imachi, H., Yoshimoto, T., Kikuchi, F., Fukunaga, K., Sato, S., Ibata, T., Yamaji, N., Lyu, J., et al. (2018) · Journal of Medical Case Reports · doi:10.1186/s13256-018-1708-x · Cited by 34

A comparison of graph- and kernel-based –omics data integration algorithms for classifying complex traits

Yan, K. K., Zhao, H., & Pang, H. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1982-4 · Cited by 34

Immunotherapy Resistance in Glioblastoma

Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34

Modulation of immune checkpoint molecule expression in mantle cell lymphoma

Harrington, B. K., Wheeler, E., Hornbuckle, K., Shana’ah, A. Y., Youssef, Y., Smith, L., Hassan II, Q., Klamer, B., Zhang, X., Long, M., et al. (2019) · Leukemia & Lymphoma · doi:10.1080/10428194.2019.1569231 · Cited by 31

Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

Alves Costa Silva, C., Piccinno, G., Suissa, D., Bourgin, M., Schreibelt, G., Durand, S., Birebent, R., Fidelle, M., Sow, C., Aprahamian, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45357-1 · Cited by 33

Engineering cell heterogeneity into organs-on-a-chip

Mertz, D. R., Ahmed, T., & Takayama, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00413g · Cited by 33

Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control

Hughes, M. S., Zheng, H., Zubiri, L., Molina, G. E., Chen, S. T., Mooradian, M. J., Allen, I. M., Reynolds, K. L., & Dougan, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2397 · Cited by 32

CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer

Lam, J. H., Hong, M., Koo, S.-L., Chua, C. W. L., Lim, K. L., Wee, F., Wan, W. K., Leow, W. Q., Yeo, J. G., Tan, I. B. H., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-02859-x · Cited by 31

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., & Janowitz, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx181 · Cited by 32

Molecular mechanism of triple‑negative breast cancer‑associated BRCA1 and the identification of signaling pathways

Qi, F., Qin, W., & Zang, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9884 · Cited by 32

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib

Yoon, J., Apicelli, A. J., & Pavlopoulos, T. V. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.11.001 · Cited by 32